Henrik Søeborg

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
New insulin analogues with a longer duration of action and a flatter pharmacodynamic profile are developed to improve convenience and safety for diabetic patients. During the nonclinical development of such analogues, safety studies must be conducted in nondiabetic rats, which consequently are rendered chronically hypoglycemic. A rat comparator model using(More)
  • 1